Accuray Incorporated (NASDAQ:ARAY) Stock Position Trimmed by Tudor Investment Corp ET AL

Tudor Investment Corp ET AL trimmed its position in shares of Accuray Incorporated (NASDAQ:ARAY) by 64.1% in the fourth quarter, HoldingsChannel reports. The firm owned 108,362 shares of the medical equipment provider’s stock after selling 193,399 shares during the period. Tudor Investment Corp ET AL’s holdings in Accuray were worth $215,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors also recently made changes to their positions in the company. Heartland Advisors Inc. boosted its position in shares of Accuray by 14.1% during the fourth quarter. Heartland Advisors Inc. now owns 3,824,750 shares of the medical equipment provider’s stock worth $7,573,000 after buying an additional 472,800 shares during the period. Renaissance Technologies LLC boosted its position in Accuray by 6.8% during the 4th quarter. Renaissance Technologies LLC now owns 2,979,998 shares of the medical equipment provider’s stock worth $5,900,000 after acquiring an additional 189,414 shares during the period. Geode Capital Management LLC grew its stake in shares of Accuray by 0.3% in the fourth quarter. Geode Capital Management LLC now owns 2,186,154 shares of the medical equipment provider’s stock worth $4,329,000 after purchasing an additional 6,758 shares in the last quarter. Archon Capital Management LLC increased its holdings in shares of Accuray by 11.5% during the fourth quarter. Archon Capital Management LLC now owns 888,662 shares of the medical equipment provider’s stock valued at $1,760,000 after purchasing an additional 91,796 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. raised its stake in shares of Accuray by 2.0% during the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 283,280 shares of the medical equipment provider’s stock valued at $561,000 after purchasing an additional 5,421 shares in the last quarter. Institutional investors and hedge funds own 64.08% of the company’s stock.

Accuray Price Performance

Shares of NASDAQ:ARAY opened at $1.52 on Friday. The stock has a market cap of $155.79 million, a price-to-earnings ratio of -30.30 and a beta of 1.30. The company has a debt-to-equity ratio of 3.51, a current ratio of 1.62 and a quick ratio of 0.88. Accuray Incorporated has a 12 month low of $1.28 and a 12 month high of $2.95. The stock’s 50 day moving average price is $1.64 and its 200 day moving average price is $1.91.

Accuray (NASDAQ:ARAY) last posted its quarterly earnings data on Wednesday, April 30th. The medical equipment provider reported ($0.01) EPS for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.04. The company had revenue of $113.24 million for the quarter, compared to the consensus estimate of $101.53 million. Accuray had a negative return on equity of 9.75% and a negative net margin of 0.96%. Equities research analysts anticipate that Accuray Incorporated will post 0.01 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, StockNews.com lowered shares of Accuray from a “buy” rating to a “hold” rating in a research report on Monday, May 5th.

About Accuray

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. It offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate.